Literature DB >> 25239268

Oritavancin: first global approval.

Anthony Markham1.   

Abstract

Oritavancin (Orbactiv(®)) is a lipoglycopeptide antibacterial drug with activity against Gram-positive bacteria developed by The Medicines Company as a single-dose treatment for acute bacterial skin and skin structure infections (ABSSSI). The drug received its first global approval for this indication in the US in August 2014, and is under regulatory review in the EU. This article summarises the milestones in the development of oritavancin leading to this first approval for the treatment of ABSSSIs caused by Gram-positive bacteria.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25239268     DOI： 10.1007/s40265-014-0295-4

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  9 in total

1.  Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.

Authors:  Gerald J Fetterly; Christine M Ong; Sujata M Bhavnani; Jeffrey S Loutit; Steven B Porter; Lisa G Morello; Paul G Ambrose; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study.

Authors:  Borje Darpo; Sun K Lee; Thomas E Moon; Nancy Sills; Jay W Mason
Journal:  J Clin Pharmacol       Date:  2010-05-19       Impact factor: 3.126

3.  Oritavancin microbiologic features and activity results from the surveillance program in the United States.

Authors:  Rodrigo E Mendes; David J Farrell; Helio S Sader; Ronald N Jones
Journal:  Clin Infect Dis       Date:  2012-04       Impact factor: 9.079

4.  Oritavancin: mechanism of action.

Authors:  George G Zhanel; Frank Schweizer; James A Karlowsky
Journal:  Clin Infect Dis       Date:  2012-04       Impact factor: 9.079

Review 5.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

6.  Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.

Authors:  Lala M Dunbar; Joe Milata; Ty McClure; Margaret M Wasilewski
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

7.  Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia.

Authors:  Christopher M Rubino; Scott A Van Wart; Sujata M Bhavnani; Paul G Ambrose; Jill S McCollam; Alan Forrest
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

8.  Single-dose oritavancin in the treatment of acute bacterial skin infections.

Authors:  G Ralph Corey; Heidi Kabler; Purvi Mehra; Sandeep Gupta; J Scott Overcash; Ashwin Porwal; Philip Giordano; Christopher Lucasti; Antonio Perez; Samantha Good; Hai Jiang; Greg Moeck; William O'Riordan
Journal:  N Engl J Med       Date:  2014-06-05       Impact factor: 91.245

9.  Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.

Authors:  Geoffrey A McKay; Sylvain Beaulieu; Francis F Arhin; Adam Belley; Ingrid Sarmiento; Thomas Parr; Gregory Moeck
Journal:  J Antimicrob Chemother       Date:  2009-04-15       Impact factor: 5.790
  9 in total
  12 in total

1.  Vancomycin C-Terminus Guanidine Modifications and Further Insights into an Added Mechanism of Action Imparted by a Peripheral Structural Modification.

Authors:  Zhi-Chen Wu; Michael D Cameron; Dale L Boger
Journal:  ACS Infect Dis       Date:  2020-07-14       Impact factor: 5.084

2.  N-Terminus Alkylation of Vancomycin: Ligand Binding Affinity, Antimicrobial Activity, and Site-Specific Nature of Quaternary Trimethylammonium Salt Modification.

Authors:  Zhi-Chen Wu; Nicholas A Isley; Dale L Boger
Journal:  ACS Infect Dis       Date:  2018-08-08       Impact factor: 5.084

3.  Total syntheses and initial evaluation of [Ψ[C(═S)NH]Tpg⁴]vancomycin, [Ψ[C(═NH)NH]Tpg⁴]vancomycin, [Ψ[CH₂NH]Tpg⁴]vancomycin, and their (4-chlorobiphenyl)methyl derivatives: synergistic binding pocket and peripheral modifications for the glycopeptide antibiotics.

Authors:  Akinori Okano; Atsushi Nakayama; Kejia Wu; Erick A Lindsey; Alex W Schammel; Yiqing Feng; Karen C Collins; Dale L Boger
Journal:  J Am Chem Soc       Date:  2015-03-09       Impact factor: 15.419

4.  Maxamycins: Durable Antibiotics Derived by Rational Redesign of Vancomycin.

Authors:  Zhi-Chen Wu; Dale L Boger
Journal:  Acc Chem Res       Date:  2020-11-02       Impact factor: 22.384

5.  Exploration of the site-specific nature and generalizability of a trimethylammonium salt modification on vancomycin: A-ring derivatives.

Authors:  Zhi-Chen Wu; Dale L Boger
Journal:  Tetrahedron       Date:  2019-02-04       Impact factor: 2.457

6.  Peripheral modifications of [Ψ[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics.

Authors:  Akinori Okano; Nicholas A Isley; Dale L Boger
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-30       Impact factor: 11.205

Review 7.  Total Syntheses of Vancomycin-Related Glycopeptide Antibiotics and Key Analogues.

Authors:  Akinori Okano; Nicholas A Isley; Dale L Boger
Journal:  Chem Rev       Date:  2017-04-24       Impact factor: 60.622

8.  C1-CBP-vancomycin: Impact of a Vancomycin C-Terminus Trimethylammonium Cation on Pharmacological Properties and Insights into Its Newly Introduced Mechanism of Action.

Authors:  Zhi-Chen Wu; Nicholas A Isley; Akinori Okano; William J Weiss; Dale L Boger
Journal:  J Org Chem       Date:  2019-10-31       Impact factor: 4.354

9.  Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.

Authors:  Jordan R Smith; Juwon Yim; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

10.  New agents approved for treatment of acute staphylococcal skin infections.

Authors:  Jan Tatarkiewicz; Anna Staniszewska; Magdalena Bujalska-Zadrożny
Journal:  Arch Med Sci       Date:  2016-05-11       Impact factor: 3.318
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.